Tag Archives: ENTA

Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.87 Per Share

Equities analysts forecast that Enanta Pharmaceuticals (NASDAQ:ENTA) will report earnings of $0.87 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.68 and the highest estimate coming in at $1.05. Enanta Pharmaceuticals posted earnings per share of ($0.44) during the same quarter last year, which would suggest a positive year-over-year growth rate of 297.7%. The company is expected to issue its next earnings results on Monday, August 6th.

On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $2.97 per share for the current fiscal year, with EPS estimates ranging from $2.39 to $3.55. For the next year, analysts anticipate that the business will report earnings of $2.77 per share, with EPS estimates ranging from $1.86 to $3.67. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The company had revenue of $44.00 million during the quarter, compared to the consensus estimate of $40.77 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. The company’s quarterly revenue was up 388.9% compared to the same quarter last year.

ENTA has been the subject of a number of recent research reports. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. ValuEngine upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 10th. Royal Bank of Canada boosted their target price on shares of Enanta Pharmaceuticals to $78.00 and gave the company a “sector perform” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 8th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $63.60.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,225 shares of the business’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $85.58, for a total transaction of $361,575.50. Following the sale, the vice president now directly owns 10,225 shares of the company’s stock, valued at approximately $875,055.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Treasurer Paul J. Mellett sold 9,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $86.48, for a total transaction of $778,320.00. Following the sale, the treasurer now directly owns 96,458 shares in the company, valued at $8,341,687.84. The disclosure for this sale can be found here. 10.56% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Teachers Advisors LLC raised its stake in Enanta Pharmaceuticals by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 28,668 shares of the biotechnology company’s stock valued at $1,682,000 after purchasing an additional 825 shares during the period. Aperio Group LLC increased its stake in shares of Enanta Pharmaceuticals by 14.1% in the first quarter. Aperio Group LLC now owns 7,288 shares of the biotechnology company’s stock worth $590,000 after acquiring an additional 899 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 3.3% in the fourth quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock worth $1,825,000 after acquiring an additional 997 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 27.0% in the first quarter. Cubist Systematic Strategies LLC now owns 5,850 shares of the biotechnology company’s stock worth $473,000 after acquiring an additional 1,243 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of Enanta Pharmaceuticals by 3.4% in the first quarter. New York State Teachers Retirement System now owns 39,790 shares of the biotechnology company’s stock worth $3,219,000 after acquiring an additional 1,300 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ENTA opened at $104.65 on Wednesday. Enanta Pharmaceuticals has a one year low of $101.89 and a one year high of $105.57. The firm has a market cap of $1.97 billion, a PE ratio of 36.37 and a beta of 1.05.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.87 Per Share

Equities analysts forecast that Enanta Pharmaceuticals (NASDAQ:ENTA) will report earnings of $0.87 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.68 and the highest estimate coming in at $1.05. Enanta Pharmaceuticals posted earnings per share of ($0.44) during the same quarter last year, which would suggest a positive year-over-year growth rate of 297.7%. The company is expected to issue its next earnings results on Monday, August 6th.

On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $2.97 per share for the current fiscal year, with EPS estimates ranging from $2.39 to $3.55. For the next year, analysts anticipate that the business will report earnings of $2.77 per share, with EPS estimates ranging from $1.86 to $3.67. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. Enanta Pharmaceuticals had a return on equity of 18.50% and a net margin of 31.60%. The company had revenue of $44.00 million during the quarter, compared to the consensus estimate of $40.77 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. The company’s quarterly revenue was up 388.9% compared to the same quarter last year.

ENTA has been the subject of a number of recent research reports. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. ValuEngine upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 10th. Royal Bank of Canada boosted their target price on shares of Enanta Pharmaceuticals to $78.00 and gave the company a “sector perform” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 8th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $63.60.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,225 shares of the business’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $85.58, for a total transaction of $361,575.50. Following the sale, the vice president now directly owns 10,225 shares of the company’s stock, valued at approximately $875,055.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Treasurer Paul J. Mellett sold 9,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $86.48, for a total transaction of $778,320.00. Following the sale, the treasurer now directly owns 96,458 shares in the company, valued at $8,341,687.84. The disclosure for this sale can be found here. 10.56% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Teachers Advisors LLC raised its stake in Enanta Pharmaceuticals by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 28,668 shares of the biotechnology company’s stock valued at $1,682,000 after purchasing an additional 825 shares during the period. Aperio Group LLC increased its stake in shares of Enanta Pharmaceuticals by 14.1% in the first quarter. Aperio Group LLC now owns 7,288 shares of the biotechnology company’s stock worth $590,000 after acquiring an additional 899 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 3.3% in the fourth quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock worth $1,825,000 after acquiring an additional 997 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 27.0% in the first quarter. Cubist Systematic Strategies LLC now owns 5,850 shares of the biotechnology company’s stock worth $473,000 after acquiring an additional 1,243 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of Enanta Pharmaceuticals by 3.4% in the first quarter. New York State Teachers Retirement System now owns 39,790 shares of the biotechnology company’s stock worth $3,219,000 after acquiring an additional 1,300 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors.

Shares of NASDAQ:ENTA opened at $104.65 on Wednesday. Enanta Pharmaceuticals has a one year low of $101.89 and a one year high of $105.57. The firm has a market cap of $1.97 billion, a PE ratio of 36.37 and a beta of 1.05.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com